Palatin initiates Phase 2 study of bremelanotide/PDE5i combo for ED non-responders

PALATIN TECHNOLOGIES INC

Approximately 30–40% of ED patients do not respond to PDE5i monotherapy.
Phase 2 trial of bremelanotide co-formulated with a PDE5i expected to start Q4 2023.
Published data show synergy between bremelanotide and PDE5i via distinct mechanisms.
Bremelanotide is the active agent in Vyleesi, approved for HSDD in women.
Palatin successfully co-formulated bremelanotide with a PDE5i for single injection.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.